Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer

British Journal of Cancer

Volumn 91, Issue 7, 2004, Pages 1301-1307

  Swinson, D E B ^a   Cox, G ^b   O'Byrne, K J ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b KING S MILL HOSPITAL   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

CA IX; EGFR; MMP 9; NSCLC

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; UNCLASSIFIED DRUG; CA9 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; BIOSYNTHESIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; THEORETICAL MODEL;

ADULT; AGED; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MODELS, THEORETICAL; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 6944233742     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602149     Document Type: Article

References (44)

1. Abdollahi A, Bao R, Hamilton TC (1999) Lot1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein. Oncogene 18: 6477-6487
2. Bailey LR, Janas M, Schmidt K, Bindsley N, Wolf M, Grous J, Askaa J, Herbst R, Johnson D, Giaccone G (2004) Evaluation of epidermal growth factor receptor (egfr) as a predictive marker in patients with non-small cell lung cancer (nsclc) receiving first-line gentifinib combined with cisplatin based chemotherapy. Proc Am Soc Clin Oncol 23: 618
3. Clarke K, Smith K, Gullick WJ, Harris AL (2001) Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a pi3 kinase dependent pathway. Br J Cancer 84: 1322-1329
4. Cohen S, Carpenter G, King Jr L (1981) Epidermal growth factor-receptor-protein kinase interactions. Prog Clin Biol Res 66: 557-567
5. Cohen S, Carpenter G, King LJ (1980) Epidermal growth factor receptor-kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255: 4834-4842
6. Cornianu M, Tudose N (1997) Immunohistochemical markers in the morphological diagnosis of lung carcinoma. Rom J Morphol Embryol 43: 181-191
7. Cox G, Jones JL, O'Byrne KJ (2000) Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6: 2349-2355
8. D'Amico TA, Massey M, Herndon II JE, Moore MB, Harpole Jr DH (1999) A biologic risk model for stage i lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117: 736-743
9. Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A (2003) Critical role of both p27kip1 and p21cip1/waf1 in the antiproliferative effect of zd1839 ('iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195: 139-150
10. Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G, Ciardiello F (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage i-iiia non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4: 241-249
11. Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, Zhao S, Qian H, Lu HF, Xiang YB, Jiang GL (1999) Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 23: 143-152
12. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase iii trial - intact 1. J Clin Oncol 22: 777-784
13. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61: 7992-7998
14. Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D (2002) The role of ral a in epidermal growth factor receptor-regulated cell motility. Cancer Res 62: 982-985
15. Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, Niewoehner DE (1998) Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 157: 1093-1097
16. Gulli LF, Palmer KC, Chen YQ, Reddy KB (1996) Epidermal growth factor-induced apoptosis in a431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 7: 173-178
17. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH (2004a) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase iii trial - intact 2. J Clin Oncol 22: 785-794
18. Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler AB, Mass R, Johnson DH (2004b) Tribute - a phase iii trial of erlotinib hcl (osi-774) combined with carboplatin and paclitaxel (cp) chemotherapy in advanced non-small cell lung cancer (nsclc). Proc Am Soc Clin Oncol 23: 617
19. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M (2002) Zd1839 (iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62: 2554-2560
20. Hirsch FR, Varella-Garcia M, Bunn Jr PA, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798-3807
21. Hognason T, Chatterjee S, Vartanian T, Ratan RR, Ernewein KM, Habib AA (2001) Epidermal growth factor receptor induced apoptosis: potentiation by inhibition of ras signaling. FEBS Lett 491: 9-15
22. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S (2003) Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 13: 289-298
23. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004a) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, (Epub 2004 Apr 2129)
24. Lynch TJ, Lilenbaum R, Bonomi P, Ansari R, Govindan R, Janne PA, Hanna N (2004b) A phase ii trial of cetuximab as therapy for recurrent non-small cell lung cancer (nsclc). Proc Am Soc Clin Oncol 23: 634
25. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, Wanibuchi H, Fukushima S, Inoue K, Yoshikawa J (2003) Expression of epidermal growth factor receptor (egfr) and downstream-activated peptides in surgically excised non-small-cell lung cancer (nsclc). Lung Cancer 41: 123-130
26. O'Byrne KJ, Cox G, Swinson D, Richardson D, Edwards JG, Lolljee J, Andi A, Koukourakis MI, Giatromanolaki A, Gatter K, Harris AL, Waller D, Jones JL (2001) Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer 34(Suppl 2): S83-S89
27. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, Ishida S, Nagase A, Miyokawa N, Hirata S, Kikuchi K (2000) Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7: 603-607
28. Onn A, Correa AM, Gilcrease M, Moran C, Roach JS, Isobe T, Bucana CD, Hong WK, Putnam JB, Herbst RS (2003) Epidermal growth factor receptor, her2, and c-kit as predictors of outcome in stage i non-small cell lung cancer. Proc Am Soc Clin 22: 635
29. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, Epub 2004 Apr 1429
30. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F (1997) Immunocytochemical markers in stage i lung cancer: relevance to prognosis. J Clin Oncol 15: 2858-2865
31. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP (1999) Anti-epidermal growth factor receptor antibody c225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257-265
32. Pfeiffer P, Clausen PP, Andersen K, Rose C (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185her-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74: 86-91
33. Rosen K, Coll ML, Li A, Filmus J (2001) Transforming growth factor-alpha prevents detachment-induced inhibition of c-src kinase activity, bcl-xl down-regulation, and apoptosis of intestinal epithelial cells. J Biol Chem 276: 37273-37279
34. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E (1997) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3: 515-522
35. Selvaggi G, Scagliotti GV, Novello S, Leonardo E, Lausi P, Borasio P, Torri W (2002) Prospective evaluation of epidermal growth factor (egfr) expression in completely resected non-small cell lung cancer (nsclc): effects of egfr on long-term follow up. Proc Am Soc Clin 21, (Abstr 1345)
36. Semenza G (2002) Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 64: 993-998
37. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, O'Byrne KJ (2004) Hypoxia-inducible factor-1alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 111: 43-50
38. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ (2003) Carbonic anhydrase ix expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21: 473-482
39. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y (1996) A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287
40. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL (1987) Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 55: 513-516
41. Volm M, Drings P, Wodrich W (1993) Prognostic significance of the expression of c-fos, c-jun and c-erbb-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 119: 507-510
42. Westermark B, Magnusson A, Heldin CH (1982) Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res 8: 491-507
43. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60: 7075-7083
44. Yarden Y, Ullrich A (1988) Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443-478